ArticleThe Indian journal of medical research2025
Antimicrobial & anticancer activities of extracellular silver nanoparticles biosynthesised by Haloferax sp SNP6.
Article in The Indian journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & objectives Nanotechnology-based therapeutics offer promising strategies for treating infectious diseases and cancer. Silver nanoparticles (AgNPs), in particular, exhibit strong antimicrobial and anticancer properties. Biologically synthesized AgNPs are preferred for their safety and environmental compatibility. Haloferax species, known for their extremophilic nature, present a novel biosynthetic platform. This study aimed to evaluate the antimicrobial and anticancer activities of extracellular AgNPs biosynthesized by Haloferax sp SNP6 and assess their effects on selected human cancer cell lines. Methods Initially, the extracellular silver NPs were biosynthesized using Haloferax sp SNP6. These nanoparticles were then characterized using several techniques, including X-ray diffraction (XRD), transmission electron microscopy (TEM), Fourier-transform infrared spectroscopy (FTIR), and UV spectroscopy. The purpose of these analyses was to confirm the formation, size, shape, and functional groups associated with the Ag-NPs. Their antimicrobial efficacy was tested against several pathogenic bacteria and fungi using standard microbiological methods. The cytotoxic effects were assessed on human cancer cell lines (breast and cervical) and compared with those on a non-cancerous human cell line. Results The biogenic Ag-NPs via Haloferax sp exhibited significant antimicrobial activity against Escherichia coli (ATCC 8739), Bacillus subtilis (ATCC 6633), Pseudomonas aeruginosa (ATCC 90274), Staphylococcus aureus (ATCC 6538), Aspergillus niger, and Candida albicans (ATCC 10221), which possessed clear zones of 18±1.1, 28±1.7, 24±1.3, 18±1.2, 0, and 27±2.0, respectively. The biogenic Ag-NPs via Haloferax sp (Hal-AgNPs) demonstrated potent cytotoxic effects on cancer cell lines, with lower IC50 values indicating higher efficacy and minimal toxicity toward non-cancerous cells. The NPs presented a unique combination of size, stability, and surface characteristics, contributing to their biological activities. The TEM image of Hal-AgNPs demonstrated semi-spherical-shaped particles ranging from 2 to 14 nm, and XRD proved that the Hal-AgNPs are crystalline. Interpretation & conclusions The observed findings of this study suggest a dual functionality of the biosynthesized silver nanoparticles (Hal-AgNPs) as antimicrobials and anticancer agents highlighting their potential as therapeutic agents, especially in treating drug-resistant infections and cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.